Valuation: Labcorp Holdings Inc.

Capitalization 20.76B 17.77B 16.53B 15.41B 28.79B 1,871B 30.88B 190B 74.85B 895B 77.84B 76.25B 3,282B P/E ratio 2025 *
21.2x
P/E ratio 2026 * 18.4x
Enterprise value 25.58B 21.91B 20.37B 18.99B 35.49B 2,306B 38.06B 235B 92.24B 1,103B 95.94B 93.97B 4,044B EV / Sales 2025 *
1.83x
EV / Sales 2026 * 1.71x
Free-Float
99.96%
Yield 2025 *
1.15%
Yield 2026 * 1.16%
More valuation ratios * Estimated data
Dynamic Chart
01-08 Labcorp's Early Development Medical Device Testing Unit Acquired by NAMSA MT
01-08 Visby Engages Quest and Labcorp to Broaden Consumer Access to First At-Home, FDA-Authorized PCR Test for STIs CI
01-08 Visby engages Quest and Labcorp to broaden consumer access to first at-home, FDA-authorized PCR test for STIs RE
01-08 Namsa announces strategic acquisition of select assets of the early development medical device testing business of Labcorp RE
01-08 North American Science Associates, LLC acquired Early Development Medical Device Testing Business of Labcorp Holdings Inc. (NYSE:LH). CI
12-16 Labcorp Holdings Inc. Announces Retirement of Mark Schroeder as Executive Vice President and President, Diagnostics Laboratories and Chief Operations Officer, Effective April 1, 2026 CI
12-15 Cofactor Genomics, Inc. announced that it has received $4.489513 million in funding from Labcorp Holdings Inc., Ascension Ventures, LLC CI
12-15 Cofactor Genomics announces strategic investment by LabCorp and Ascension Ventures RE
12-11 Labcorp Holdings Inc. Announces Retirement of Dr. D. Gary Gilliland from Board of Directors, Effective December 31, 2025 CI
12-03 Community Health Systems Sells Select Outreach Lab Assets to Labcorp for $194 Million MT
12-02 Labcorp Holdings Inc. (NYSE:LH) completed the acquisition of Select assets of the ambulatory outreach laboratory services from CHS/Community Health Systems, Inc. for approximately $194 million. CI
11-24 Labcorp Appoints Victor Bulto to Board of Directors, Effective December 1, 2025 CI
11-24 Cofactor Genomics, Inc. announced that it expects to receive $4.489513 million in funding from Labcorp Holdings Inc., Ascension Ventures, LLC CI
More news
1 day-0.56%
1 week-1.10%
Current month-0.20%
1 month-5.22%
3 months-9.89%
6 months+0.31%
Current year-0.20%
More quotes
1 week 248.79
Extreme 248.79
261.73
1 month 245
Extreme 245
266.99
Current year 245
Extreme 245
261.73
1 year 209.38
Extreme 209.375
293.72
3 years 191.97
Extreme 191.97
293.72
5 years 191.97
Extreme 191.97
317.17
10 years 97.79
Extreme 97.79
317.17
More quotes
Change 5d. change 1-year change 3-years change Capi.($)
-0.56%-1.10%+7.93%-0.77% 20.76B
+0.48%-0.73%+56.63%+85.90% 108B
+0.07%-0.07%+67.38%-9.89% 102B
+0.37%+6.31%+46.79%+78.52% 33.36B
+0.15%+6.95%-12.80%+19.23% 24.38B
+0.86%+1.41%+15.91%+18.78% 19.57B
-0.79%-3.57%+55.98%+290.24% 17.54B
-0.07%+0.51%+57.94%+53.30% 16.93B
-0.52%-7.59%+12.59%+40.89% 12.87B
-2.24%-2.02%-8.63%+20.57% 13.26B
Average -0.28%+0.20%+29.97%+59.68% 36.89B
Weighted average by Cap. -0.07%+0.39%+45.37%+50.21%
See all sector performances

Financials

2025 *2026 *
Net sales 13.99B 11.98B 11.14B 10.39B 19.41B 1,261B 20.82B 128B 50.46B 603B 52.48B 51.4B 2,212B 14.62B 12.52B 11.64B 10.86B 20.28B 1,318B 21.76B 134B 52.72B 630B 54.83B 53.71B 2,312B
Net income 939M 804M 748M 697M 1.3B 84.66B 1.4B 8.62B 3.39B 40.5B 3.52B 3.45B 149B 1.08B 926M 861M 803M 1.5B 97.48B 1.61B 9.92B 3.9B 46.64B 4.06B 3.97B 171B
Net Debt 4.82B 4.13B 3.84B 3.58B 6.69B 435B 7.18B 44.25B 17.4B 208B 18.09B 17.72B 763B 4.22B 3.61B 3.36B 3.13B 5.85B 380B 6.27B 38.67B 15.2B 182B 15.81B 15.48B 666B
More financial data * Estimated data
Logo Labcorp Holdings Inc.
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. The Company provides insights and advanced science to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The Biopharma Laboratory Services segment consists of early development research laboratories and central laboratory services. The Company is also focused on clinical diagnostics and reproductive and women's health in the United States outside of New York and New Jersey.
Employees
65,450
More about the company
Date Price Change Volume
12/01/26 250.39 $ -0.56% 876,042
09/01/26 251.81 $ -1.12% 507,695
08/01/26 254.67 $ +0.37% 680,745
07/01/26 253.73 $ -2.56% 603,012
06/01/26 260.40 $ +2.85% 659,237

Delayed Quote Nyse, January 13, 2026 at 12:00 am

More quotes
Trader
Investor
Global
Quality
ESG MSCI
AA
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
250.39USD
Average target price
299.71USD
Spread / Average Target
+19.70%
Consensus

Quarterly revenue - Rate of surprise